| 翻訳と辞書 |
| Kevin Johnson (venture capitalist) ： ウィキペディア英語版 |
Kevin Johnson (venture capitalist)
Kevin Johnson (born in Holyhead, Wales on 30 August 1960) is a Partner at Index Ventures life sciences practice and works out of the London office. Kevin joined the venture capital firm in 2010 with a focus on new assets in the biologics area, which will enable the firm to build companies based on the asset-centric model of biotech investment pioneered by Index.
== Education and career ==
Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.
From 1990 onwards, Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research and in 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer. Kevin led both the development of CAT's platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development, including the first such drug, Humira™ to reach the market. He was also part of the management team that floated CAT on the London Stock Exchange (main market).
Since 2004, Kevin worked with Index Ventures Life Sciences team as a venture advisor. Prior to his return to Index he was CEO of PanGenetics (acquired by Abbott Laboratories), an antibody development company based in the Netherlands, and one of the Index Ventures portfolio companies.〔()〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Kevin Johnson (venture capitalist)」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|